BIOYF (Biosyent) Cash Flow for Dividends: $-1.68 Mil (TTM As of Mar. 2026)


BIOYF Biosyent Inc BIOYF
98 GF Score
Price $10.26
GF Value $11.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biosyent Cash Flow for Dividends?

Biosyent BIOYF +4.06% 98 Cash Flow for Dividends is $-1.68 Mil as of Mar. 2026. GuruFocus rates BIOYF with a GF Score™ of 98/100 and a GF Value™ of $11.25 (Fairly Valued). The stock has 4 warning signs investors should review.

Biosyent's cash flow for dividends for the three months ended in Mar. 2026 was $-0.45 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.68 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Biosyent's quarterly payment of dividends increased from Sep. 2025 ($-0.41 Mil) to Dec. 2025 ($-0.41 Mil) and increased from Dec. 2025 ($-0.41 Mil) to Mar. 2026 ($-0.45 Mil).

Biosyent's annual payment of dividends increased from Dec. 2023 ($-1.43 Mil) to Dec. 2024 ($-1.46 Mil) and increased from Dec. 2024 ($-1.46 Mil) to Dec. 2025 ($-1.63 Mil).

Biosyent Cash Flow for Dividends Related Terms

Biosyent Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Biosyent's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent Cash Flow for Dividends Chart

Biosyent Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.36 -1.43 -1.46 -1.63

Biosyent Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.41 -0.41 -0.41 -0.45
BIOYF
98GF Score
Biosyent Inc BIOYF
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosyent Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $-1.68 Mil mean?
Biosyent (BIOYF) has a Cash Flow for Dividends of $-1.68 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Biosyent and its competitors.
Is Biosyent's Cash Flow for Dividends too high?
Biosyent's current Cash Flow for Dividends is $-1.68 Mil. Overall, Biosyent has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's Cash Flow for Dividends compare to ZTS and UTHR?
Biosyent's Cash Flow for Dividends of $-1.68 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Biosyent and its competitors. Biosyent's current Cash Flow for Dividends is $-1.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (BIOYF) is currently considered Fairly Valued. The stock's GF Value™ is $11.25, compared to a current price of $10.26 — trading 8.8% below its estimated fair value. The current Cash Flow for Dividends is $-1.68 Mil. Biosyent's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Biosyent (BIOYF), the current Cash Flow for Dividends is $-1.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosyent (BIOYF) Overvalued in 2026?

Based on GuruFocus' analysis, Biosyent stock appears to be undervalued. The current stock price of $10.26 is trading 8.8% below its estimated GF Value™ of $11.25. GuruFocus considers Biosyent to be Fairly Valued.

Key valuation signals for BIOYF:

  • Cash Flow for Dividends: $-1.68 Mil
  • GF Value™: $11.25 vs. price of $10.26 (8.8% below fair value)
  • GF Score™: 98/100 with 4 warning signs

No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosyent Business Description

Other Exchanges RX:Canada
Address 2476 Argentia Road, Suite 402, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score

Get the complete analysis for BIOYF

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.26
Price
$11.25
GF Value